期刊文献+

普拉克索重要中间体合成路线改进研究 被引量:1

The Improved Synthetic Route for the Intermediate of Pramipexole
下载PDF
导出
摘要 普拉克索是一种帕金森病症的新型治疗药物,对其研究具有重要意义。文章通过前人对普拉克索合成的研究进行探讨,并且由此寻找到一条新的普拉克索中间体合成路线。本实验以反式对氨基环己醇为原料,经丙酰化保护氨基,Jones试剂氧化和溴化,再与硫脲进行Hantzsch反应,最后还原得到普拉克索中间体(R,S)-2-氨基-6-丙酰胺基-4,5,6,7-四氢苯并噻唑。通过最后中间体的1H-NMR谱图等可以确定其结构与目标相符,验证了该路线的可行性。 Pramipexole is a new treatment of Parkinson's disease, the study for its synthesis has important significance. In the paper, on the base of previous studies of synthesis of Pramipexole, we managed to find a new synthetic route to intermediates of pramipexole, which was efficient and convenient. In the experiment, we took trans-amino cyclohexanol as starting materials, through the five-step reaction, such as propylation, Jones oxidization, bromination, hantzsch reaction and reduction, finally we got well-quality intermediates of pramipexole in overall yield 10.90 %. We adopted 1H-NMR to determine the structure of the intermediate. That was in line with the target to verify the feasibility of the route.
出处 《广东化工》 CAS 2013年第17期50-51,共2页 Guangdong Chemical Industry
关键词 普拉克索 合成 工艺研究 Pramipexole synthesis process research
  • 相关文献

参考文献6

  • 1金有豫.药理学[M].第五版.北京:人民卫生出版社,2002.255.
  • 2余丹丽,张雄.普拉克索在帕金森病中的应用[J].实用医学杂志,2009,25(1):20-21. 被引量:30
  • 3Schneider,Mierau J. Dopamine Autoreceptor Agonists: Resolution andPharmacological Activity of 2,6-DiamiQOtetrahydrob^zQthia.)le and anAminotiiiazole Anaglogue of Apomorophine[J]. J. Med. Chem.,1987,30: 494.
  • 4MistryD N, Soni K S, Vasoya S L,et al. Improved process for thepreparation of biologicdly active tetrahydrobenzothiazole derivative[P]. W02006003677 , 2006.
  • 5BalickiR. Sypniewski M, CiesielskaA, et al. Prot^ss for prq>aration ofpramipexole base and/or its salts[P]. W02007075095,2007.
  • 6Schneider,Mierau J. Dopamine Autorec印tor Agonists: Resolution andPharmacological Activity of 2,6-DiaminotetrahydrobCTzothiazole md anAmiBothiazole Anaglogue of Apomorophine[J]. J. Med. Chem. , 1987,30: 494.

二级参考文献20

  • 1Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole [J]. J Neurochem, 2003,87 (3) :631-641.
  • 2Okura T, Ito T, Ishiguro N, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist [J]. Life Sciences, 2007,80 (17) : 1564-1571.
  • 3Parkison Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group [J]. JAMA, 2000,284(15):1931-198.
  • 4Noyes K, Dick A W, Holloway R G. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life [ J ]. Value Health, 2006,9 ( 1 ) : 28- 38.
  • 5Constantinescu R, Romer M, McDermott M P, et al. Impact of pramipexole on the onset of levodopa-related dyskinesias[J]. Mov Disord, 2007,22(9) : 1317-1319.
  • 6Parkison Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage[J]. Clin Neuropharmacol, 2007,30(2) :72-85.
  • 7Moller J C, Oertel W H, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial [ J ]. Mov Disord, 2005,20 (5) : 602- 610.
  • 8Weiner W J, Factor S A, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease [J]. Parkinsonism Relat Disord, 2001,7(2) : 115-120.
  • 9Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkiuson's Disease [J]. N Engl J Med, 2007,356( 1 ) : 39-46.
  • 10Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease [ J ]. J Neurol, 2004,251 (3) : 335-339.

共引文献38

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部